

European Heart Journal

Volume 44 No. 32 August 2023

ISSUE @ A GLANCE



Antithrombotic treatment: personalized antiplatelet therapies and lessons from the gut microbiota
F. Crea 3023

CardioPulse



Are we ready for cell-specific therapies in atherosclerosis?
A.W. Khan 3027

Investigator Nazha Hamdani MD, PhD, talks to CardioPulse about her love of science and why we may be closer than we think to unravelling a clinical conundrum
J. Ozkan 3031

Implementation of a national primary percutaneous coronary intervention program for ST-segment elevation myocardial infarction in the Kingdom of Bahrain: an inspiring success story from a centre of excellence
H. Amin, H.A. Noor, F. Bardooli, and N. Yousif 3034

Weekly Journal Scan

Heart failure and socioeconomic status: global differences and inequalities
R. Vergallo and C. Patrono 3038

FOCUS ISSUE ON THROMBOSIS AND ANTITHROMBOTIC TREATMENT

SPECIAL ARTICLE

Management of patients on antithrombotic therapy with severe infections: a joint clinical consensus statement of the ESC Working Group on Thrombosis, the ESC Working Group on Atherosclerosis and Vascular Biology, and the International Society on Thrombosis and Haemostasis
B. Gigante, J.H. Levy, E. van Gorp, A. Bartoloni, M.-L. Bochaton-Piallat, M. Bäck, H. ten Cate, C. Christersson, J.L. Ferreira, T. Geisler, E. Lutgens, S. Schulman, R.F. Storey, J. Thachil, G. Vilahur, P.C. Liaw, and B. Rocca 3040

STATE OF THE ART REVIEW



Personalised antiplatelet therapies for coronary artery disease: what the future holds
D. Capodanno and D.J. Angiolillo 3059

META-ANALYSIS

Diagnostic management of acute pulmonary embolism: a prediction model based on a patient data meta-analysis
N. van Es, T. Takada, N. Kraaijpoel, F.A. Klok, M.A.M. Stals, H.R. Büller, D.M. Courtney, Y. Freund, J. Galipienzo, G. Le Gal, W. Ghanima, M.V. Huisman, J.A. Kline, K.G.M. Moons, S. Parpia, A. Perrier, M. Righini, H. Robert-Ebadi, P.-M. Roy, P.S. Wells, K. de Wit, M. van Smeden, and G.-J. Geersing 3073

Editorial

A novel prediction model for pulmonary embolism: from dichotomizing algorithms to personalized likelihood
T.A. Zelniker and I.M. Lang 3082

CLINICAL RESEARCH



Atlas of gut microbe-derived products from aromatic amino acids and risk of cardiovascular morbidity and mortality
I. Nemet, X.S. Li, A. Haghikia, L. Li, J. Wilcox, K.A. Romano, J.A. Buffa, M. Witkowski, I. Demuth, M. König, E. Steinhagen-Thiessen, F. Bäckhed, M.A. Fischbach, W.H.W. Tang, U. Landmesser, and S.L. Hazen 3085

Editorial

A roadmap for gut microbiome-derived aromatic amino acids for improved cardiovascular risk stratification
B.E. Stähli, M. Scharl, and C.M. Matter 3097

DISCUSSION FORUM

Comparison of bleeding risk between standard ticagrelor and prasugrel therapies without de-escalation strategy

S. Şen

3100

Comparison of standard ticagrelor and prasugrel therapies based on previous trials

J. Kang, K.W. Park, and H.-S. Kim

3102

CARDIOVASCULAR FLASHLIGHT

Intravenous thrombolysis for bioprosthetic valve thrombosis

R. Adrichem, R.P.J. Budde, and N.M. Van Mieghem

3104



This paper is Editor's Choice and is available free online at <https://academic.oup.com/eurheartj>



Open Access Paper



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>

CON

The
a mo
treat
antith
ical co
Throm
and Va
Thromb
Karolin
author
tion
but, dr
instan
logy n
Euras
public h
ment wh
sity to
level of
Congest
mortality
and drug
over. This
demonstr
of patients
concomit
to the pap
and bleed
ing associa
Concomit
gently and
management
antiplatlet th
factors holds
ble and drug

Printed in the UK



www.eurheartj.org